Both in Biotechnology
Monte Rosa Therapeutics vs Cullinan Therapeutics
Over the past year GLUE returned +60.6% and CGEM returned +155.1%; their daily moves had a correlation of 0.38.
GLUE +60.6% CGEM +155.1%Growth of $1, one year, split-adjusted
| Metric | GLUE | CGEM |
|---|---|---|
| Price | $11.74 | $15.23 |
| Market cap | $1.00B | $980.1M |
| Today | +0.26% | +1.87% |
| 1 month | −12.3% | −29.8% |
| 6 months | −24.4% | +13.5% |
| Year to date | −25.1% | +47.1% |
| 1 year | +56.7% | +155.5% |
| Revenue growth (YoY) | −61.3% | — |
| Gross margin | 100.0% | — |
| Net margin | −483.9% | — |
| P/E (TTM) | — | — |
| Price / sales | 34.9× | — |
| Net cash | $621.1M | $334.5M |
| Dividend yield | — | — |
| Volatility (60d) | 81.8% | 72.3% |
| Short % of float | 39.1% | 18.0% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).